Balchem Corporation

Valuation Analysis

About the Company

Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; a

Balchem Corporation Stock at a Glance

Balchem Corporation (BCPC) is currently trading at $165.04 with a market capitalization of $5.3B. The trailing P/E ratio stands at 33.89x, with a forward P/E of 27.01x. The 52-week range spans from $139.17 to $183.90; the current price is 10.3% below the yearly high. Year-over-year revenue growth stands at +8.1%. The net profit margin stands at 14.95%.

💰 Dividend

Balchem Corporation pays an annual dividend of $0.96 per share, representing a yield of 0.58%. The payout ratio stands at 19.71%.

📊 Analyst Rating

4 analysts rate Balchem Corporation (BCPC) on consensus: None. The average price target is $200.75, implying +21.64% from the current price. Analyst price targets range from $164.00 to $234.00.

Balchem Corporation: The Investment Case in Detail

Balchem Corporation (BCPC) operates in the Basic Materials — specifically Specialty Chemicals — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

At a PEG of 3.79, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

What to Watch Next

• The forward P/E of 27.01x is meaningfully below the trailing 33.89x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 21.64% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Balchem Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.